# JP-14: A Trace Amine-Associated Receptor 1 Agonist with Anti-Metabolic Disorder Potential

## TL;DR

JP-14 is a new TAAR1 agonist that improves glucose and lipid metabolism, showing potential for treating metabolic disorders like obesity.

## Contribution

JP-14 is a novel aminoguanidine-based TAAR1 agonist with demonstrated anti-metabolic disorder effects.

## Key findings

- JP-14 promotes glucose uptake in HepG2 cells and reduces lipid deposition in 3T3-L1 adipocytes.
- JP-14 reduces intracellular neutral and phospholipids in adipocytes, showing anti-steatotic and anti-phospholipidotic activity.
- JP-14 delays gastric emptying in mice, similar to loperamide, and prevents fructose-induced lipid accumulation in zebrafish.

## Abstract

TAAR1 agonists have emerged as promising therapeutic agents capable of modulating glucose homeostasis, enhancing insulin secretion and suppressing appetite, making them attractive candidates for the treatment of obesity and related metabolic disorders. Despite their potential, the number of TAAR1-targeting compounds with well-defined pharmacological profiles remains limited. In this study, we identified and characterized JP-14, a novel aminoguanidine-based TAAR1 agonist, in a comprehensive panel of pharmacological assays. JP-14 promoted glucose uptake in HepG2 cells and reduced lipid deposition during 3T3-L1 adipocyte differentiation, with both actions dependent on TAAR1 signaling. In differentiated 3T3-L1 adipocytes, JP-14 reduced intracellular levels of both neutral lipids and phospholipids, indicating dual anti-steatotic and anti-phospholipidotic activity. In zebrafish larvae, toxicity profiling confirmed 10 µg/mL as a safe concentration for further in vivo studies. These assays showed that JP-14 promoted lipid mobilization and partially prevented fructose-induced lipid accumulation, demonstrating systemic metabolic benefits in vivo. Moreover, JP-14 markedly delayed gastric emptying in mice, an effect similar to loperamide and reversed by TAAR1 antagonism, supporting its role in regulating satiety and energy balance. Collectively, our findings establish JP-14 as a safe and metabolically active TAAR1 agonist with multifaceted effects on glucose and lipid metabolism. JP-14 represents a valuable pharmacological tool for probing TAAR1-mediated mechanisms in metabolic regulation.